logo
Plus   Neg
Share
Email

Exasol AG Planning An IPO In Frankfurt For 2020 - Quick Facts

German data analytics firm Exasol AG announced Tuesday that it is now planning an initial public offering of their shares on the Frankfurt Stock Exchange in 2020.

The company plans to invest the initial proceeds of the IPO to support their growth strategy, primarily in the areas of client base expansion, brand awareness, and increased internationalization.

In October 2019, Exasol completed a pre-IPO placement of shares to a small number of long-term investors, paving the way for an initial public offering in 2020.

Hauck & Aufhauser acted as Sole Global Coordinator and Sole Bookrunner for the private placement and has been appointed as Sole Global Coordinator and Sole Bookrunner for the IPO.

The company said it will provide further details concerning the planned IPO in due course. The IPO will not only provide the necessary growth funding but will also materially increase the growth rate by creating global awareness for the Exasol brand and pave the road for further internationalization.

Founded in 2000, Exasol has developed and refined a unique analytics database, purpose-built for the growing demand for data-driven business. Its high-performance in-memory analytics database gives organizations the ability to transform how they work with data, on-premises, in the cloud or both.

The company has employees spread across its offices in Nuremberg, Berlin, London, Paris, and Atlanta and offers high-end database solutions for an array of high-profile customers.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry. Graco Inc. (GGG) shares were climbing more than 7 percent in morning trade. Monday after market close, the company had reported a surge in the fourth-quarter earnings to $84.8 million from $73.7 million in the prior year. Earnings per share surpassed analysts' estimates. Sales were up 1 percent to $412.3... Strategy of getting multiple indication approvals for the same drug seems to be paying off for AstraZeneca PLC (AZN), in terms of higher likelihood of approval and improved sales. Besides, the company is realizing value from non-core, mature brands to invest in new drugs, which also seems to be working in its favor.
Follow RTT
>